Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 versus sorafenib in previously treated metastatic renal cell carcinoma
NL-OMON36586Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing TKI258 with Sorafenib (2 arms). Primary endpoint: Progression-free survival. Started Jun 2011; status: active, not recruiting.
02
Drugs
dovitinibsorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON36586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36586.